Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports

Eunso Lee,Jeong Yun Jang,Jinho Yang

DOI: https://doi.org/10.3390/cancers16101896

2024-05-17

Cancers

Abstract:Background: This study aimed to systematically review case reports documenting rare adverse events in patients with small cell lung cancer (SCLC) following the administration of immune checkpoint inhibitors (ICIs). Methods: A systematic literature review was conducted to identify case reports detailing previously unreported adverse drug reactions to ICIs in patients with SCLC. The scope of the literature reviewed was restricted to case studies on SCLC published up to 31 December 2023. Results: We analyzed twenty-four studies on ICI use for patients with SCLC. There were six reports on atezolizumab, four on durvalumab, and three on adverse events from monotherapy with nivolumab. Reports involving combination treatments were the most frequent, with a total of six, predominantly involving using nivolumab in combination with ipilimumab. Additionally, there was one report each on using pembrolizumab, nofazinilimab, sintilimab, tislelizumab, and toripalimab. We collected detailed information on the clinical course, including patient and disease characteristics, symptoms, treatment for each adverse event, and recovery status. Among the patients included in the case reports, 21 out of 24 (87.5%) had extensive-stage SCLC when initiating ICI therapy, with only 1 patient diagnosed with limited-stage SCLC. Respiratory system adverse events were most common, with seven cases, followed by neurological, endocrinological, and gastroenterological events. Three case reports documented adverse events across multiple systems in a single patient. In most cases, patients showed symptom improvement; however, four studies reported cases where patients either expired without symptom improvement or experienced sequelae. Conclusions: Efforts to develop reliable biomarkers for predicting irAEs continue, with ongoing research to enhance predictive precision. Immunotherapy presents diverse and unpredictable adverse events, underscoring the need for advanced diagnostic tools and a multidisciplinary approach to improve patient management.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify rare adverse events that occur during the treatment of small - cell lung cancer (SCLC) patients with immune checkpoint inhibitors (ICIs). Specifically, the study aims to systematically review and analyze relevant case reports to understand the characteristics, incidence rates, and potential impacts on patients of these rare adverse events. Through this research, the authors hope to provide a comprehensive overview of the uncommon side effects that may be caused by ICIs in SCLC, thereby helping clinicians better manage and prevent these adverse events.

### Main research questions:
1. **Identify rare adverse events**: Identify rare adverse events that occur in small - cell lung cancer patients receiving ICIs treatment through systematic literature review.
2. **Describe adverse event characteristics**: Record in detail the types, occurrence times, symptoms, treatments, and recovery situations of these adverse events.
3. **Evaluate the impact of adverse events**: Analyze the impact of these adverse events on patients' health, including symptom improvement, serious consequences (such as death or persistent sequelae), etc.
4. **Propose management suggestions**: Based on the research results, propose suggestions for improving patient management and safety, emphasizing the importance of developing reliable biomarkers and multidisciplinary strategies.

### Research background:
- **Small - cell lung cancer (SCLC)**: SCLC is a type of lung cancer with a poor prognosis, and the effects of traditional treatment methods are limited.
- **Immune checkpoint inhibitors (ICIs)**: In recent years, ICIs have been widely used in the treatment of various cancers and have shown significant efficacy, but at the same time, they have also brought unpredictable immune - related adverse events (irAEs).
- **Research significance**: Since the application of ICIs in SCLC is relatively new, there are few reports on its rare adverse events, so it is necessary to systematically review existing case reports to fill this knowledge gap.

### Methods:
- **Literature search**: Search for relevant case reports published by December 31, 2023, through the Cochrane Library, PubMed, and EMBASE databases.
- **Inclusion criteria**: Only include English - language literature and meet the Population, Intervention, Comparison, Outcomes, and Study (PICOS) criteria.
- **Data extraction**: Systematically extract key features, including basic patient information, disease status, types and doses of ICIs used, diagnosis of adverse events, symptoms, treatments, and recovery situations.
- **Quality assessment**: Use the Pierson scoring system to assess the quality of each case report.

### Results:
- **Number of studies**: Finally, 24 studies were analyzed, involving multiple ICIs, including atezolizumab, durvalumab, nivolumab, and their combination therapies.
- **Types of adverse events**: The most common adverse events occurred in the respiratory system (7 cases), followed by the nervous system (5 cases), the endocrine system (4 cases), and the digestive system (4 cases).
- **Characteristics of adverse events**: Most patients' symptoms improved, but some patients also had serious consequences, including death or persistent sequelae.

### Conclusions:
- **Research findings**: The adverse events caused by ICIs in SCLC patients are diverse and unpredictable, and further research is needed to develop reliable biomarkers.
- **Clinical significance**: Emphasizes the importance of multidisciplinary teams in managing these complex adverse events to improve patients' treatment effects and safety.

Through this study, the authors hope to be able to provide more comprehensive information for clinicians to better understand and manage rare adverse events of ICIs in SCLC treatment.